STIM1 promotes acquired resistance to sorafenib by attenuating ferroptosis in hepatocellular carcinoma  

作　　者：Ran Ren Yu Chen Yu Zhou Luyao Shen Yang Chen Juan Lei Jingchun Wang Xudong Liu Nan Zhang Dongqin Zhou Huakan Zhao Yongsheng Li 

机构地区：[1]Chongqing University Cancer Hospital,School of Medicine,Chongqing University,Chongqing 400044,China [2]Department of Medical Oncology,Chongqing University Cancer Hospital,Chongqing 400030,China [3]The Second School of Medicine,Wenzhou Medical University,Wenzhou,Zhejiang 325027,China [4]Department of Gastroenterology,Xinqiao Hospital,Army Medical University,Chongqing 400037,China

出　　处：《Genes & Diseases》2024年第6期466-481,共16页基因与疾病（英文）

基　　金：supported by the Major International (Regional)Joint Research Program of the National Natural Science Foundation of China (No.81920108027);the National Natural Science Foundation of China (No.82273212);Chongqing Postgraduate Research and Innovation Project (China) (No.CYS23130);Chongqing Outstanding Youth Science Foundation (China) (No.cstc2020jcyj-jqX0030);Chongqing Science and Technology Innovation Leading Talent Support Program (China) (No.cstc2021ycjh-bgzxm0073).

摘　　要：Dysregulated calcium(Ca?+)signaling pathways are associated with tumor cell death and drug resistance.In non-excitable cells,such as hepatocellular carcinoma(HcC)cells,the primary pathway for Ca2+influx is through stromal interaction molecule 1(STIM1)-mediated store-operated calcium entry(SOCE).Previous studies have demonstrated the involvement of STIM1-mediated SOCE in processes such as genesis,metastasis,and stem cell self-renewal of HCC.However,it remains unclear whether STIM1-mediated SOCE plays a role in developing acquired resistance to sorafenib in HcC patients.In this study,we established acquired sorafenib-resistant(SR)HCC cell lines by intermittently exposing them to increasing concentrations of sorafenib.Our results showed higher levels of STIM1 and stronger SOCE in SR cells compared with parental cells.Deleting STIM1 significantly enhanced sensitivity to sorafe-nib in SR cells,while overexpressing STIM1 promoted SR by activating SOCE.Mechanistically,STIM1 increased the transcription of SLC7A11 through the SOCE-CaN-NFAT pathway.Subse-quently,up-regulated SLC7A11 increased glutathione synthesis,resulting in ferroptosis insen-sitivity and SR.Furthermore,combining the SOCE inhibitor SKF96365 with sorafenib significantly improved the sensitivity of sR cells to sorafenib both in vitro and in vivo.These findings suggest a potential strategy to overcome acquired resistance to sorafenib in HcC cells.

关 键 词：Ferroptosis Hepatocellular carcinoma SLC7A11 Sorafenib resistance STIM1 

分 类 号：R735.7[医药卫生—肿瘤]